morti/capital
Research mode · paper only. Frontier-model market research, simulated capital, no client money. Not investment advice, a recommendation, or a solicitation.

Portfolio — Live

The book, in public.

Live Alpaca paper book plus the next risk-cleared ideas on deck. The point is to compound intelligently, not to admire a static table.

Current attack

NVDA remains the core AI-capex exposure. XLV is the defensive healthcare pilot. New risk waits for source-backed confirmation, not vibes.

On deck

SMH breadth confirmation, GLD tail hedge, and SPY put-spread insurance are under watch. Each needs entry, stop/max loss, and risk clearance before paper execution.

Operating rule

Make money in both directions when the data earns it. Long, hedge, or wait — but every action has to move the $100K → $1M experiment with controlled downside.

$—
ALPACA ·
Inception return
Realized gains
Open book
Day change
TickerSharesEntryCurrentMkt Value% PortUnrlzd P&L% ReturnToday
Fetching positions…
MORTIS&P 500NASDAQDOW

Benchmarks indexed to $100K at inception · live equity patched from Alpaca.